Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Long-Term Deferred Tax (2025)

Historic Long-Term Deferred Tax for Neuphoria Therapeutics (NEUP) over the last 1 years, with Q2 2025 value amounting to $26.1 million.

  • Neuphoria Therapeutics' Long-Term Deferred Tax changed N/A to $26.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $26.1 million, marking a year-over-year change of. This contributed to the annual value of $26.1 million for FY2025, which is N/A changed from last year.
  • Neuphoria Therapeutics' Long-Term Deferred Tax amounted to $26.1 million in Q2 2025.
  • In the past 5 years, Neuphoria Therapeutics' Long-Term Deferred Tax registered a high of $26.1 million during Q2 2025, and its lowest value of $26.1 million during Q2 2025.